SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer
about
Maximising the potential of AKT inhibitors as anti-cancer treatmentsEffect of Akti-2 on sperm motility, capacitation and acrosome reaction in a mouse modelEmerging therapeutic targets in metastatic progression: A focus on breast cancer.The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer.AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity.E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancer
P2860
SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
SU2C phase Ib study of paclita ...... s and metastatic breast cancer
@ast
SU2C phase Ib study of paclita ...... s and metastatic breast cancer
@en
type
label
SU2C phase Ib study of paclita ...... s and metastatic breast cancer
@ast
SU2C phase Ib study of paclita ...... s and metastatic breast cancer
@en
prefLabel
SU2C phase Ib study of paclita ...... s and metastatic breast cancer
@ast
SU2C phase Ib study of paclita ...... s and metastatic breast cancer
@en
P2093
P2860
P356
P1476
SU2C phase Ib study of paclita ...... s and metastatic breast cancer
@en
P2093
Ana M Gonzalez-Angulo
Argun Akcakanat
Aysegul A Sahin
Emily Tarco
Eric P Winer
Gordon B Mills
Huiqin Chen
Kim-Anh Do
Kirk S Culotta
P2860
P356
10.1093/JNCI/DJU493
P407
P577
2015-02-16T00:00:00Z